论文部分内容阅读
目的 探讨持续静滴顺铂与口服依托泊甙 (VP - 16 )治疗非小细胞肺癌 (NSCLC)。方法 6 1例晚期NSCLC随机分为治疗组 (33例 )、对照组 (2 8例 )。对照组予常规EP方案。治疗组予顺铂 2 0mg/m2 /日持续静滴 4天及VP - 16胶囊 5 0mgBid× 10天。结果 有效率 (CR +PR)治疗组(5 7 6 % )高于对照组 (32 1% ,P <0 0 5 ) ;治疗组消化道反应及肾毒性小 ,生活质量改善明显 (P <0 0 5 )。结论 持续静滴顺铂与口服VP - 16胶囊为晚期NSCLC有效、安全的治疗方案
Objective To investigate the effects of continuous intravenous cisplatin and oral etoposide (VP - 16) on non - small cell lung cancer (NSCLC). Methods Sixteen patients with advanced NSCLC were randomly divided into treatment group (33 cases) and control group (28 cases). Control group to conventional EP program. The treatment group was treated with cisplatin 20 mg / m2 / day for 4 days and VP - 16 capsule 50 mg Bid × 10 days. Results The CR + PR treatment group (57.6%) was higher than the control group (32.1%, P <0.05). The treatment group had less digestive tract reaction and nephrotoxicity, and the quality of life improved significantly (P <0. 0 5). Conclusion Continuous intravenous cisplatin and oral VP - 16 capsule are effective and safe treatment for advanced NSCLC